Although immune checkpoint blockades (ICBs) targeting the programmed cell death 1 (PD-1)/PD-ligand (L)1 axis have achieved clinical success for many cancer types, the clinical efficacy of anti-PD-1/PD-L1 blockades in <i>EGFR</i> mutated NSCLC patients has been demonstrated to be lower than those without <i>EGFR</i> mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.